Evidence map›Paper›PMID 36434906›Full record

ArticleVirology2023

Production of cytoplasmic type citrus leprosis virus-like particles by plant molecular farming.

Oscar A Ortega-Rivera, Veronique Beiss, Elizabeth O Osota, Soo Khim Chan, Sweta Karan, Nicole F Steinmetz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Oscar A Ortega-RiveraDepartment of NanoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA; Center for Nano-ImmunoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA.
Veronique BeissDepartment of NanoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA; Center for Nano-ImmunoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA.
Elizabeth O OsotaDepartment of NanoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA; Center for Nano-ImmunoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA.
Soo Khim ChanDepartment of NanoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA; Center for Nano-ImmunoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA.
Sweta KaranDepartment of NanoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA; Center for Nano-ImmunoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA.
Nicole F SteinmetzDepartment of NanoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA; Center for Nano-ImmunoEngineering, University of California-San Diego, La Jolla, CA, 92039, USA; Institute for Materials Discovery and Design, University of California-San Diego, La Jolla, CA, 92039, USA; Department of Bioengineering, University of California-San Diego, La Jolla, CA, 92039, USA; Department of Radiology, University of California-San Diego, La Jolla, CA, 92039, USA; Moores Cancer Center, University of California-San Diego, La Jolla, CA, 92039, USA. Electronic address: nsteinmetz@ucsd.edu.
University of California San Diego · US

Funding

Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.U01CA218292 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, STEINMETZ, NICOLE FRANZISKA · 2017 to 2021
$3.0M
Cancer Researchers in Nanotechnology (CRIN)T32CA153915 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUMMEL, ANDREW CLYDE, ZHANG, DONG-ER · 2017 to 2021
$994k
mRNA COVID-19 Vaccines Delivered with Plant Virus/Polymer DevicesR21AI161306 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POKORSKI, JONATHAN KYLE, STEINMETZ, NICOLE FRANZISKA · 2021 to 2022
$435k
NCI NIH HHS R01 CA224605NCI NIH HHS T32 CA153915NCI NIH HHS U01 CA218292NIAID NIH HHS R21 AI161306
6 · The paper itself

Abstract

Many plant virus-like particles (VLPs) utilized in nanotechnology are 30-nm icosahedrons. To expand the VLP platforms, we produced VLPs of Cytoplasmic type citrus leprosis virus (CiLV-C) in Nicotiana benthamiana. We were interested in CiLV-C because of its unique bacilliform shape (60-70 nm × 110-120 nm). The CiLV-C capsid protein (p29) gene was transferred to the pTRBO expression vector transiently expressed in leaves. Stable VLPs were formed, as confirmed by agarose gel electrophoresis, transmission electron microscopy and size exclusion chromatography. Interestingly, the morphology of the VLPs (15.8 ± 1.3 nm icosahedral particles) differed from that of the native bacilliform particles indicating that the assembly of native virions is influenced by other viral proteins and/or the packaged viral genome. The smaller CiLV-C VLPs will also be useful for structure-function studies to compare with the 30-nm icosahedrons of other VLPs.

Indexed as

CitrusRhabdoviridaeRNA VirusesMolecular FarmingVirion

Identifiers

PMID36434906
PMCPMC9812895
OpenAlexW4309683110

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.